FI120237B - Pantropisk neurotrofin-polypeptid - Google Patents

Pantropisk neurotrofin-polypeptid Download PDF

Info

Publication number
FI120237B
FI120237B FI964833A FI964833A FI120237B FI 120237 B FI120237 B FI 120237B FI 964833 A FI964833 A FI 964833A FI 964833 A FI964833 A FI 964833A FI 120237 B FI120237 B FI 120237B
Authority
FI
Finland
Prior art keywords
hngf
trka
binding
ngf
neurotrophin
Prior art date
Application number
FI964833A
Other languages
English (en)
Finnish (fi)
Other versions
FI964833A (sv
FI964833A0 (sv
Inventor
Leonard G Presta
Roman Urfer
John Winslow
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22962278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI120237(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI964833A publication Critical patent/FI964833A/sv
Publication of FI964833A0 publication Critical patent/FI964833A0/sv
Application granted granted Critical
Publication of FI120237B publication Critical patent/FI120237B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (17)

1. Pantropisk neurotrofin-polypeptid innehällande en human NT-3 (hNT-3) eller human NGF (hNGF) aminosyrasekvens där har substituerats en aminosyra i en aminosyraposition som motsvarar positionen D15 i NT3 eller positionen D16 i hNGF, kännetecknadav att substitutionen ästadkommer trkB-bindning vid vilken nämnda D15-substituerade pantropiska hNT3 binder sig till reseptorerna trkB och trkC samt nämnda D16-substituerade hNGF binder sig till reseptorn trkB och minst tvä andra neurotrofinreseptorer som valts bland reseptorerna trkA, trkC och gp75.
2. Polypeptid enligt patentkrav 1, känneteck-n a d av att nämnda substitution är en alaninrest.
3. Polypeptid enligt patentkrav 2, känneteck-n a d av att nämnda alaninrest är substituerad i den position som motsvarar positionen D15 i hNT3.
• 4. Polypeptid enligt patentkrav 3, känneteck-n a d av att nämnda substitutionsposition är D15A i hNT3. • · • · · • · · • · •j.
5. Polypeptid enligt patentkrav 3, känneteck . .·. n a d av att där vidare har substituerats de sex första ♦ · · .·.·. aminosyrorna med nägon av följande aminosyrasekvenser: (1) de • · · sex första aminosyrorna i NGF, (2) YAEHKS, (3) YASHPIF, (4) ... YAHPIF, (5) YASHPIS, (6) YAEHPIF och (7) YAQHPIF.
• · · • · · • · ’*:** 6. Polypeptid enligt patentkrav 2 där har substituerats en alaninrest i en position som motsvarar positionen D16 i hNGF, kännetecknadav att nämnda polypeptid binder sig 1. till reseptorerna trkB, trkA och gp75. • · ·«·
7. Polypeptid enligt patentkrav 6, känneteck-n a d av att nämnda substitutionsposition är D16A i hNGF.
8. Polypeptid enligt patentkrav 6, känneteck^ n a d av att där vidare finns en substitution i förvariabelt omräde 1 för aminosyrorna V18, V20 och G23 sarat minst en substitution i variabelt omräde 4 för aminosyrorna Y79, T81, H84, F86 eller K88 för att astadkomma trkC-bindningsaktivitet med vilken den substituerade D16A hNGF dessutom binder sig till reseptorn trkC.
9. Polypeptid enligt patentkrav 8, känneteck-n a d av att där finns en substitution i positionerna D16A, V18E, V20L, G23T, Y79Q, T81K, H84Q, F86Y och K88R.
10. Polypeptid enligt patentkrav 9, känneteck--n a d av att den är D16A, V18E, V20L, G23T, Y79Q, T81K, H84Q, F86Y, K88R NGF till sin uppbyggnad.
11. Polypeptid enligt patentkrav 6, känneteck-n a d av att där dessutom finns en substitution i aminosyrapositionerna E41, K57, D72 eller N77 för att astadkomma • · · • *: en dylik större trkA-bindningsaktivitet. ·· · • · · t · • ·
12. Polypeptid enligt nägot av de föregäende • · .:. patentkraven 1-11, kännetecknadav att den innehäller • ·· · . .·. en kovalent heterodimer eller en kovalent homodimer. • · · • · · ··· • · · • · ·
13. Isolerad nukleinsyra, kännetecknadav ... att den kodar en polypeptid enligt nägot av de föregäende • · · *·]/ patentkraven 1-12.
• · • · • · · . : 14. Expressionsvektor, kännetecknadav att ··· den innehäller nukleinsyran enligt patentkrav 13. • · · • · « • · • i
15. Vardcell, kännetecknadav att den innehäller nukleinsyran enligt patentkrav 13.
16. Forfarande för framställning av polypeptiden enligt nägot av de foregäende patentkraven 1 - 12, kannetec-k n a t av att vid förfarandet utsatts en värdcell innehällande en nukleinsyra som kodar nämnda polypeptid för forhällanden som expresserar nämnda polypeptid.
17. Farmaceutisk sammansättning innehällande polypeptiden enligt nägot av de foregäende patentkraven 1 -12 hopblandad med en farmaceutiskt acceptabel excipient. ·· · • · · • · • · ·· · • · · • · • · • · • * · • · · • · ··· ···♦ • · · • · · ··· ··· • · · » · · ··· • · · • · · • •t • · • · ··· • · · • · · ··· ··· • · • · ··· 1 • · • · • · ···
FI964833A 1994-06-03 1996-12-03 Pantropisk neurotrofin-polypeptid FI120237B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25393794A 1994-06-03 1994-06-03
US25393794 1994-06-03
PCT/US1995/006918 WO1995033829A1 (en) 1994-06-03 1995-06-01 Pantropic neurotrophic factors
US9506918 1995-06-01

Publications (3)

Publication Number Publication Date
FI964833A FI964833A (sv) 1996-12-03
FI964833A0 FI964833A0 (sv) 1996-12-03
FI120237B true FI120237B (sv) 2009-08-14

Family

ID=22962278

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964833A FI120237B (sv) 1994-06-03 1996-12-03 Pantropisk neurotrofin-polypeptid

Country Status (17)

Country Link
US (6) US5728803A (sv)
EP (1) EP0763107B1 (sv)
JP (1) JPH10501138A (sv)
CN (1) CN1159439C (sv)
AT (1) ATE280825T1 (sv)
AU (1) AU695144B2 (sv)
BR (1) BR9508019B1 (sv)
CA (1) CA2191064C (sv)
DE (1) DE69533698T2 (sv)
ES (1) ES2231786T3 (sv)
FI (1) FI120237B (sv)
IL (1) IL113983A0 (sv)
MX (1) MX9605971A (sv)
NO (1) NO317938B1 (sv)
NZ (1) NZ287762A (sv)
PT (1) PT763107E (sv)
WO (1) WO1995033829A1 (sv)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
DE19637718A1 (de) 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
WO1998021234A2 (en) 1996-11-15 1998-05-22 Genentech, Inc. Purification of neurotrophins
US6391571B1 (en) 1997-04-01 2002-05-21 Roche Diagnostics Gmbh Recombinant inactive avidin mutants
US6365373B2 (en) 1997-04-25 2002-04-02 Genentech, Inc. Nucleic acids encoding NGF variants
EP0977860A1 (en) * 1997-04-25 2000-02-09 Genentech, Inc. Ngf variants
US7452863B1 (en) 1997-04-29 2008-11-18 Genentech, Inc. NGF variants
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
GB0024550D0 (sv) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
CA2448956C (en) * 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
WO2006072005A2 (en) * 2004-12-30 2006-07-06 The Johns Hopkins University Methods for high efficiency survival/proliferation of human embyonic stem cells and human embyro survival in culture
PT2120997T (pt) * 2006-12-21 2017-05-05 H Lundbeck As Modulação da atividade de proneurotrofinas
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
WO2017157325A1 (zh) * 2016-03-18 2017-09-21 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
CN112409471B (zh) * 2016-04-13 2022-07-29 舒泰神（北京）生物制药股份有限公司 低痛神经生长因子突变体
CN110183536B (zh) * 2018-02-22 2021-01-15 中国科学院遗传与发育生物学研究所 一种复合支架材料及其应用
EP3823674A4 (en) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
CN110812532A (zh) * 2019-08-20 2020-02-21 中山大学 一种靶向促进皮质脊髓束连接以修复脊髓损伤的组织工程支架的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5488099A (en) * 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
US5349055A (en) * 1992-03-06 1994-09-20 Persson Hakan B Nerve growth factor having altered receptor binding specificities
AU4535993A (en) * 1992-06-12 1994-01-04 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
US5753225A (en) * 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
AU1282895A (en) * 1993-12-29 1995-07-17 Sumitomo Pharmaceuticals Company, Limited Novel human ciliary neurotrophic factor
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US7144983B1 (en) * 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors

Also Published As

Publication number Publication date
CA2191064A1 (en) 1995-12-14
DE69533698T2 (de) 2006-02-09
US6503728B1 (en) 2003-01-07
AU695144B2 (en) 1998-08-06
NO317938B1 (no) 2005-01-10
JPH10501138A (ja) 1998-02-03
BR9508019B1 (pt) 2012-06-12
FI964833A (sv) 1996-12-03
IL113983A0 (en) 1995-10-31
FI964833A0 (sv) 1996-12-03
ES2231786T3 (es) 2005-05-16
DE69533698D1 (de) 2004-12-02
PT763107E (pt) 2005-02-28
BR9508019A (pt) 1997-09-09
US5981480A (en) 1999-11-09
NZ287762A (en) 1999-01-28
US5728803A (en) 1998-03-17
NO965123L (no) 1997-02-03
CA2191064C (en) 2009-11-03
EP0763107B1 (en) 2004-10-27
CN1159439C (zh) 2004-07-28
US7935671B2 (en) 2011-05-03
AU2659295A (en) 1996-01-04
US20060270838A1 (en) 2006-11-30
MX9605971A (es) 1997-12-31
US6333310B1 (en) 2001-12-25
NO965123D0 (no) 1996-12-02
US7528233B2 (en) 2009-05-05
CN1153528A (zh) 1997-07-02
WO1995033829A1 (en) 1995-12-14
ATE280825T1 (de) 2004-11-15
EP0763107A1 (en) 1997-03-19
US20100184656A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
FI120237B (sv) Pantropisk neurotrofin-polypeptid
Urfer et al. The binding epitopes of neurotrophin‐3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin.
Lai et al. Cloning and expression of a novel neurotrophin, NT-7, from carp
US6365373B2 (en) Nucleic acids encoding NGF variants
Lu BDNF and activity-dependent synaptic modulation
Allendoerfer et al. Regulation of neurotrophin receptors during the maturation of the mammalian visual system
Battleman et al. HSV-1 vector-mediated gene transfer of the human nerve growth factor receptor p75hNGFR defines high-affinity NGF binding
Soppet et al. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor
Ebendal Function and evolution in the NGF family and its receptors
US8101571B2 (en) Treatment methods using NGF variants
Ibanez et al. An extended surface of binding to Trk tyrosine kinase receptors in NGF and BDNF allows the engineering of a multifunctional pan‐neurotrophin.
Borasio et al. ras p21 protein promotes survival and fiber outgrowth of cultured embryonic neurons
Feng et al. Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons
Suter et al. NGF/BDNF chimeric proteins: analysis of neurotrophin specificity by homolog-scanning mutagenesis
Allsopp et al. Ectopic trkA expression mediates a NGF survival response in NGF-independent sensory neurons but not in parasympathetic neurons.
Escandon et al. Characterization of neurotrophin receptors by affinity crosslinking
US7144983B1 (en) Pantropic neurotrophic factors
EP0674660B1 (en) Multifunctional neurotrophic factors
AU691915B2 (en) Biologically active EPH family ligands
AU2002300365B2 (en) NGF Variants
Kullander et al. Specificity of neurotrophin‐3 determined by loss‐of‐function mutagenesis
Jaber et al. Expression of polyadenylated and non-polyadenylated TrkC transcripts in the roent central nervous system

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120237

Country of ref document: FI

MA Patent expired